Physician profile
David M Kuphal
NPI 1417999269
$16,896.95
in general payments reported to CMS, 2019-2025
29 companies · $3,792 in 2025
The $3,792 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,326 · 2022: $2,873 · 2023: $3,962 · 2024: $3,944 · 2025: $3,792.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $822.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,875.94 |
| Education | $822.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,792.70 | 2021-2025 | |
| Regeneron Healthcare Solutions, INC. | $1,983.50 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $1,354.60 | 2021-2025 | Ilumya, Odomzo, Blu-U |
| Lilly USA, LLC | $1,268.20 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Janssen Biotech, INC. | $1,151.42 | 2021-2025 | Tremfya, Simponi Aria, Simponi |
| Ucb, INC. | $1,057.37 | 2021-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $976.36 | 2021-2025 | |
| Arcutis Biotherapeutics, INC. | $971.83 | 2023-2025 | Zoryve |
| E.R. Squibb & Sons, L.L.C. | $915.51 | 2022-2025 | Sotyktu |
| Novartis Pharmaceuticals Corporation | $880.26 | 2021-2025 | |
| Amgen INC. | $722.24 | 2021-2025 | Otezla, Otezla |
| Incyte Corporation | $712.64 | 2022-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $626.41 | 2021-2025 | |
| Dermavant Sciences, INC. | $345.80 | 2022-2024 | Vtama |
| Galderma Laboratories, L.P. | $244.82 | 2021-2025 | Aklief, Oracea |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $175.50 | 2025 | Hadlima, Vtama |
| Sanofi-Aventis U.S. LLC | $169.98 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $125.00 | 2022 | |
| Leo Pharma INC. | $89.07 | 2022-2025 | Adbry |
| Vyne Pharmaceuticals INC. | $57.86 | 2021 | |
| Organogenesis INC. | $57.51 | 2023-2024 | Cygnus Dual, Puraply |
| Dermira, INC. | $50.93 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.10 | 2023-2025 | Spevigo |
| Paratek Pharmaceuticals, INC. | $29.78 | 2024 | Nuzyra |
| Mylan Institutional INC. | $25.82 | 2023 | |
| Fresenius Kabi USA, LLC | $25.76 | 2023 | Idacio |
| Sandoz INC. | $21.66 | 2024 | Hyrimoz |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $15.14 | 2021 | |
| Botanix Sb INC | $14.18 | 2025 | Sofdra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Kuphal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.